Self-Replicating RNA Molecule with Mosso das Pedras Virus-Derived RNA Replicase
Summary
Nanjing Genscript Biotech Co., Ltd. has received USPTO Patent Application US20260109975A1 (publication date April 23, 2026; application filed January 24, 2025 under application number 19155923) covering a self-replicating RNA molecule with a defined 5-prime-to-3-prime structure including a 5-prime cap, 5-prime UTR, open reading frame encoding an RNA replicase, a promoter, a sequence of interest, a 3-prime UTR, and a poly(A) tail. The RNA replicase is a nonstructural protein or functional variant derived from one of 13 named viruses including Mosso das Pedras virus (MDPV), Everglades virus (EVEV), Rio Negro virus (RNV), Mucambo virus (MUCV), Highlands J virus (HJV), Pixuna virus (PIXV), Trocara virus (TROV), Cabassou virus (CABV), Tonate virus (TONV), Bebaru virus (BEBV), Fort Morgan virus (FMV), Getah virus (GETV), or Ndumu virus (NDUV).
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 263 changes logged to date.
What changed
The USPTO published patent application US20260109975A1 for Nanjing Genscript Biotech Co., Ltd., covering a replicable RNA molecule and its uses. The application (filed January 24, 2025) claims a structure comprising a 5-prime cap, 5-prime UTR, open reading frame encoding an RNA replicase, promoter, sequence of interest, 3-prime UTR, and poly(A) tail, where the RNA replicase is derived from one of 13 specified viruses including MDPV, EVEV, RNV, MUCV, HJV, PIXV, TROV, CABV, TONV, BEBV, FMV, GETV, or NDUV. CPC classifications span C12N 15/11, C07K 14/065, C07K 14/11, C07K 14/115, C12N 9/127, and others.
Competitors in RNA therapeutics, vaccine development, or gene therapy using self-amplifying RNA (saRNA) platforms should review this filing to assess potential freedom-to-operate considerations. The scope of Claim 1 extends to any replicable RNA construct employing a replicase from the enumerated virus family, which may affect design choices for saRNA-based product pipelines.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SELF-REPLICATING RNA AND USE THEREOF
Application US20260109975A1 Kind: A1 Apr 23, 2026
Assignee
NANJING GENSCRIPT BIOTECH CO., LTD.
Inventors
Kangming Chen, Zhen Sun, Haoyi Zhang, Fangxiang Hu
Abstract
The present application relates to a replicable RNA molecule and the use thereof. The replicable RNA molecule comprises, from the 5′ end to the 3′ end, a 5′ cap, a 5′ UTR, an open reading frame encoding an RNA replicase, a promoter, a sequence of interest, a 3′ UTR and a poly(A) tail, wherein the RNA replicase is capable of amplifying the replicable RNA molecule and is capable of amplifying an RNA molecule containing the sequence of interest and 3′ UTR, wherein the RNA replicase is a nonstructural protein or a functional variant thereof derived from Mosso das Pedras virus (MDPV), Everglades virus (EVEV), Rio Negro virus (RNV), Mucambo virus (MUCV), Highlands J virus (HJV), Pixuna virus (PIXV), Trocara virus (TROV), Cabassou virus (CABV), Tonate virus (TONV), Bebaru virus (BEBV), Fort Morgan virus (FMV), Getah virus (GETV) or Ndumu virus (NDUV).
CPC Classifications
C12N 15/11 C07K 14/065 C07K 14/11 C07K 14/115 C12N 9/127 C12Y 207/07048 C12N 2830/50 C12N 2840/203
Filing Date
2025-01-24
Application No.
19155923
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.